TLR 3 is a member of the Toll-like receptor family of pattern recognition receptors of the innate immune system. Discovered in 2001,[1] TLR3 recognizes double-stranded RNA, a form of genetic information carried by some viruses such as reoviruses. Upon recognition, TLR 3 induces the activation of NF-kB to increase production of type I interferons which signal other cells to increase their antiviral defenses. Double-stranded RNA is also recognised by the cytoplasmic receptors RIG-I and MDA-5. TLR3 has also been designated as CD283 (cluster of differentiation 283). [edit] Structure The structure of TLR3 was reported in June 2005 by researchers at The Scripps Research Institute.[2] TLR3 forms a large horseshoe shape that contacts with a neighboring horseshoe, forming a "dimer" of two horseshoes. Much of the TLR3 protein surface is covered with sugar molecules, making it a glycoprotein, but on one face (including the proposed interface between the two horseshoes), there is a large sugar-free surface. This surface also contains two distinct patches rich in positively-charged amino acids, which may be a binding site for negatively-charged double-stranded RNA. Despite being a glycoprotein, TLR3 crystallises readily - a prerequisite for structural analysis by x-ray crystallography. [edit] References - ^ Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001). "Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3". Nature 413 (6857): 732–8. doi:10.1038/35099560. PMID 11607032.
- ^ Choe J, Kelker MS, Wilson IA (2005). "Crystal structure of human toll-like receptor 3 (TLR3) ectodomain". Science 309 (5734): 581–5. doi:10.1126/science.1115253. PMID 15961631.
[edit] Further reading | PDB Gallery | | | | | 1ziw: Human Toll-like Receptor 3 extracellular domain structure | | | | 2a0z: The molecular structure of toll-like receptor 3 ligand binding domain | | | |
| Proteins: clusters of differentiation (see also list of human clusters of differentiation) | | | 1-50 | CD1 ( a-c, 1A, 1D, 1E) · CD2 · CD3 ( γ, δ, ε) · CD4 · CD5 · CD6 · CD7 · CD8 ( a) · CD9 · CD10 · CD11 ( a, b, c) · CD13 · CD14 · CD15 · CD16 ( A, B) · CD18 · CD19 · CD20 · CD21 · CD22 · CD23 · CD24 · CD25 · CD26 · CD27 · CD28 · CD29 · CD30 · CD31 · CD32 ( A, B) · CD33 · CD34 · CD35 · CD36 · CD37 · CD38 · CD39 · CD40 · CD41 · CD42 ( a, b, c, d) · CD43 · CD44 · CD45 · CD46 · CD47 · CD48 · CD49 ( a, b, c, d, e, f) · CD50 | | | 51-100 | CD51 · CD52 · CD53 · CD54 · CD55 · CD56 · CD57 · CD58 · CD59 · CD61 · CD62 ( E, L, P) · CD63 · CD64 ( A, B, C) · CD66 ( a, b, c, d, e, f) · CD68 · CD69 · CD70 · CD71 · CD72 · CD73 · CD74 · CD78 · CD79 ( a, b) · CD80 · CD81 · CD82 · CD83 · CD84 · CD85 ( a, d, e, h, j, k) · CD86 · CD87 · CD88 · CD89 · CD90 · CD91- CD92 · CD93 · CD94 · CD95 · CD97 · CD98 · CD99 · CD100 | | | 101-150 | | | | 151-200 | CD151 · CD152 · CD153 · CD154 · CD155 · CD156 ( a, b, c) · CD157 · CD158 ( a, d, e, i, k) · CD159 ( a, c) · CD160 · CD161 · CD162 · CD163 · CD164 · CD166 · CD167 ( a, b) · CD168 · CD169 · CD170 · CD171 · CD172 ( a, b, g) · CD174 · CD177 · CD178 · CD179 ( a, b) · CD181 · CD182 · CD183 · CD184 · CD185 · CD186 · CD191 · CD192 · CD193 · CD194 · CD195 · CD196 · CD197 · CDw198 · CDw199 · CD200 | | | 201-250 | | | | 251-300 | | | | 301-350 | | | | Transmembrane receptors: immune receptors | | | Cytokine receptor | | | Interleukins (2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 21, 23, 27) CSF receptors (EPO, GM-CSF, G-CSF) GH · prolactin · Oncostatin M · Leukemia inhibitory factor common subunits ( Common gamma chain, common beta chain, gp130) | | | | | | | | | | | | | | | | | | | Other | | | | | Other endogenous | | | | Exogenous | | | |